Strategic focus Target customers: pharmaceutical, biotech, medical device and academic institutions that require human-derived biomaterials and associated development services for research, preclinical, and clinical studies. Leverage Key Biologics’ long-standing source continuity and IRB protocol support to position as a trusted supplier for end-to-end material needs.

Lifecycle coverage Emphasize end-to-end materials supply from pre-clinical research through clinical trials and post-market production. Offer partnerships around ongoing material sourcing, donor safety training, and custom material specifications to align with customers’ long product development timelines.

Compliance edge Highlight expertise in developing and submitting research protocols to IRBs and ensuring donor safety. Position as a compliance-forward partner that can reduce customer risk and speed study approvals, a key selling point for regulated cell therapy projects.

Immunology and cell therapy Showcase capabilities in cell characterization, assay development, and immune-related product support gained from the Astarte Biologics integration. Target sponsors advancing immunotherapies, MS, and other immune-mediated conditions that rely on high-quality human-derived materials.

Expansion signals Capitalize on momentum from past acquisitions and product launches (Asymptote VIA Freeze Quad) to propose enhanced storage, handling, and cryopreservation solutions for large or distributed studies. Offer scalable material sourcing and cold-chain services to growing biotechs and academic programs.